Heinz Mäusli

About Heinz Mäusli

Heinz Mäusli, 62, is an independent Class II director at Lantheus (LNTH) serving since June 2020; he sits on the Audit Committee and the Nominating & Corporate Governance Committee and has been designated by the Board as an Audit Committee Financial Expert based on his finance credentials . He was formerly CFO of radiopharmaceutical company Advanced Accelerator Applications S.A. (2003–2018) and previously worked in strategy consulting at Accenture and Gemini; he holds an MBA from Columbia University and a Lic. oec. from the University of St. Gallen (Switzerland) .

Past Roles

External Roles

Board Governance

• Committee assignments (current): Audit Committee (member); Nominating & Corporate Governance Committee (member). All members of both committees are independent under Nasdaq and SEC rules; Audit is chaired by Samuel Leno; N&CG is chaired by Julie McHugh .
• Audit Committee Financial Expert: The Board determined that Mr. Mäusli meets the SEC’s “Audit Committee Financial Expert” definition (Item 407(d)(5) of Regulation S‑K) .
• Independence: Lantheus states nine of eleven directors are independent; all Audit, Talent & Compensation, and N&CG committees are fully independent .
• Attendance and engagement: In 2024 the Board held 9 meetings; Audit 4; N&CG 7; each director attended at least 75% of Board and applicable committee meetings. Non‑employee directors hold private executive sessions at the end of most Board meetings; Audit and N&CG also meet in executive session with Internal Audit and Compliance leaders, respectively .
• Lead Independent Director: When the Chair is non‑independent, a Lead Independent Director is appointed (currently Julie McHugh) to preside over executive sessions and other duties per guidelines .

Fixed Compensation

• Director pay structure (annualized; April 2024–April 2025 term): | Board / Committee | Chair (Cash) | Lead Independent Director (Cash) | Member (Cash) | Annual Equity Grant (Grant-date FV) | |---|---:|---:|---:|---:| | Board of Directors | $125,000 | $95,000 | $60,000 | $400,000 | | Audit Committee | $25,000 | — | $12,500 | — | | Talent & Compensation Committee | $20,000 | — | $10,000 | — | | Nominating & Corporate Governance Committee | $15,000 | — | $7,500 | — | | Science & Technology Committee | $15,000 | — | $7,500 | — |

Note: Board member cash retainer increased to $60,000 (from $55,000) and Chair to $125,000 (from $117,500) in April 2024 .

• 2024 director compensation (actual amounts): | Name | Fees Earned or Paid in Cash | Stock Awards (RSUs) | Option Awards | Total | |---|---:|---:|---:|---:| | Heinz Mäusli | $82,167 | $199,997 | $199,992 | $482,156 |

Performance Compensation

• Annual equity for non‑employee directors: In 2024, Mr. Mäusli received a standard annual grant of RSUs and stock options with the following details : | Grant Date | RSUs (#) | Options (#) | Notes | |---|---:|---:|---| | May 9, 2024 | 2,635 | 4,853 | Aggregate grant-date fair values flow through the table above; company applies ASC 718 . |
• Outstanding as of Dec 31, 2024: 2,635 unvested RSUs; options to purchase 12,719 shares outstanding, of which 4,853 options unvested .
• Observations: Director equity is time-based (no performance metric disclosure for directors); equity mix (half RSUs/half options by grant-date value in 2024) aligns director incentives with long-term share performance .

Other Directorships & Interlocks

Expertise & Qualifications

• Financial and legal background with over 20 years in molecular nuclear medicine; CFO experience at AAA (radiopharmaceuticals) .
• Audit Committee Financial Expert designation; meaningful experience across corporate finance, accounting/financial reporting, M&A (per Board skills matrix and audit expert designation) .
• Education: MBA (Columbia University); Lic. oec. (University of St. Gallen) .

Equity Ownership

• Calculation note: Percent derived using 68,480,308 shares outstanding as of March 3, 2025, per the proxy’s methodology .
• Alignment policies: Directors must hold shares equal to 3x the annual director cash retainer; until met, they must retain 50% of after‑tax shares from option exercises/RSU vesting. As of Dec 31, 2024, each director had either met the guideline or remained within the five-year compliance window. Hedging and pledging of company stock by directors is prohibited .

Governance Assessment

• Strengths

  • Independent director with deep radiopharmaceutical finance experience and designated Audit Committee Financial Expert; serves on two core governance committees (Audit; N&CG) .
  • Documented engagement: Board/committee cadence and executive sessions; each director ≥75% attendance in 2024; encourages robust oversight and independent discussion .
  • Pay alignment: Mix of cash/equity with standardized annual RSU/option grants; clear director ownership guideline and strict prohibition on hedging/pledging support long‑term alignment .
  • Compensation governance: Independent consultant (Pearl Meyer) reviews director pay; modest retainer increases based on benchmarking .
  • Broader shareholder sentiment: 2024 say‑on‑pay support ~97% (executive pay context), signaling general investor confidence in compensation governance .

• Watch items / potential risks

  • Classified board structure is under shareholder scrutiny (2025 shareholder proposal to declassify; Board made no recommendation), indicating ongoing governance debate at the company level (not specific to Mäusli) .
  • No specific related‑party transactions involving Mr. Mäusli surfaced in the proxy excerpts reviewed; the Audit Committee oversees a formal related person transaction policy (continue to monitor) .

• Summary: Mäusli brings relevant domain and financial oversight expertise, sits on key governance committees, and operates under strong alignment and trading policies. Current disclosures present no red flags on independence, attendance, or conflicts for Mäusli; overall indicators are supportive of investor confidence in his board effectiveness .